Get Started

Artificial Intelligence | Machine Learning Arcellx | Uniquely Adaptive & Controllable Cell Therapies

Enterprise, Biotechnology, Health Care, Pharmaceuticals, Drug Discovery, Cell Therapy Gaithersburg, MD, United States

Artificial Intelligence | Machine Learning

Arcellx | Uniquely Adaptive & Controllable Cell Therapies

Biotechnology, Health Care, Pharmaceuticals, Drug Discovery, Cell Therapy

Gaithersburg, MD, United States

Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive, and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases.

The Company's proprietary ARC-sparX platform separates the tumor-recognition and tumor-killing functions of conventional CAR-T cell therapies: (1) sparX (soluble protein antigen-receptor X-linkers) proteins recognize and bind specific antigens on diseased cells and flag those cells for destruction; and (2) ARC-T (Antigen Receptor Complex-T) cells bind the sparX proteins and kill the flagged cells. Arcellx has developed a collection of sparX proteins that bind different cell surface antigens. Administration of alternate sparX proteins can redirect ARC-T cells to different disease antigens to potentially address relapsed and refractory disease due to tumor heterogeneity or antigen escape. Additionally, ARC-T cell activity can be curbed as needed by controlling the dose and frequency of sparX administration.

Total Funding: $200 M

Funding Stage: Series C

Business Stage: Scaling Up

Market: B2B

Company Size: 26 to 50

Founded: 2015

Date

Round

$ Raised

Investors

04/13/2021

Series C

$115M

Adage Capital Management, Asymmetric Capital Partners, CaaS Capital, Cambrian Biopharma, CAM Capital, Clough Capital Partners, LG Technology Ventures, Andrew Schoen, Novo Holdings, Samsara BioCapital, Sixty Degree Capital, Soleus Capital, SR One, Suvretta Capital Management, Takeda Ventures, Terra Magnum Capital Partners

Date : 04/13/2021

Round: Series C

$ Raised: $115M

Investors: Adage Capital Management, Asymmetric Capital Partners, CaaS Capital, Cambrian Biopharma, CAM Capital, Clough Capital Partners, LG Technology Ventures, Andrew Schoen, Novo Holdings, Samsara BioCapital, Sixty Degree Capital, Soleus Capital, SR One, Suvretta Capital Management, Takeda Ventures, Terra Magnum Capital Partners

For AI/ML Startup Founders

Get introduced to VC/PE/CVC investors

Signup and Get Started

For Investors at VC/PE firms

Get introduced to AI/ML Startup founders or founders at Arcellx